FDA
-
-
-
-
-
-
-
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
-
-
-
-
-
-
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
-
-
-
-
-
-
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

